First-line Immune Checkpoint Inhibitor Combinations in Metastatic Renal Cell Carcinoma: Where Are We Going, Where Have We Been?
Author:
Funder
U.S. Department of Defense
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical)
Link
https://link.springer.com/content/pdf/10.1007/s40265-022-01683-6.pdf
Reference93 articles.
1. Schmidinger M, Steger G, Wenzel C, Locker GJ, Budinsky AC, Brodowicz T, et al. Sequential administration of interferon-gamma, GM-CSF, and interleukin-2 in patients with metastatic renal cell carcinoma: results of a phase II trial. J Immunother (1991). 2001;24(3):257–62.
2. Escudier B, Farace F, Angevin E, Triebel F, Antoun S, Leclercq B, et al. Combination of interleukin-2 and gamma interferon in metastatic renal cell carcinoma. Eur J Cancer. 1993;29A(5):724–8. https://doi.org/10.1016/s0959-8049(05)80354-5.
3. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002;20(1):289–96. https://doi.org/10.1200/JCO.2002.20.1.289.
4. Clark JI, Curti B, Davis EJ, Kaufman H, Amin A, Alva A, et al. Long-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2. J Investig Med. 2021;69(4):888–92. https://doi.org/10.1136/jim-2020-001650.
5. Fishman M, Dutcher JP, Clark JI, Alva A, Miletello GP, Curti B, et al. Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIM(SM) registry. J Immunother Cancer. 2019;7(1):84. https://doi.org/10.1186/s40425-019-0567-3.
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Perioperative Complications and Oncologic Outcomes of Nephrectomy Following Immune Checkpoint Inhibitor Therapy: A Multicenter Collaborative Study;European Urology Oncology;2023-12
2. When should surgery be used to supplement systemic therapy in metastatic renal cell cancer?;Journal of Thoracic Disease;2023-06
3. Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell Carcinoma;The Oncologist;2022-10-06
4. Up-front Nivolumab With or Without Salvage Ipilimumab Across International Metastatic Database Consortium Risk Groups in Metastatic Clear Cell Renal Cell Carcinoma;Journal of Clinical Oncology;2022-09-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3